Valeant Responds To Zelapar “Approvable” Letter For Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
The “complete response” contains two safety studies per FDA’s request. Safety concerns for the fast-dissolving oral selegiline include drug interactions, hypertension due to “cheese effect.” Valeant plans a mid-2005 launch for the MAO-B inhibitor.
You may also be interested in...
Somerset Emsam Gets Committee Review To Evaluate Dietary Restrictions
FDA's Psychopharmacologic Drugs Advisory Committee to meet Oct. 25-26; the panel will also discuss need for longer-term efficacy data for chronic psychiatric therapies.
Somerset Emsam Gets Committee Review To Evaluate Dietary Restrictions
FDA's Psychopharmacologic Drugs Advisory Committee to meet Oct. 25-26; the panel will also discuss need for longer-term efficacy data for chronic psychiatric therapies.
Emsam Deal Marks Bristol's Return To The Antidepressant Market
Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.